Answers are grounded in this paper and cite their sources.
Purpose of the review Lung cancer surgery creates a vulnerable perioperative window where anesthetic and physiological interventions may modulate recurrence. This review evaluates the oncological impact of perioperative strategies in non-small-cell lung cancer, proposing a comprehensive ‘oncoanesthesia care bundle’. Recent findings Current clinical data expose a persistent gap between compelling preclinical rationales and observable clinical outcomes. The recent General Anesthetics in CAncer REsection Surgery (2026), a large-scale evaluation of propofol versus volatile anesthesia, enrolled mixed cancer cohorts and demonstrated no oncological advantage of propofol, underscoring that the ongoing Inhalational Gas Anesthesia and Propofol-based Total IntraVenous Anesthesia trial will provide the first adequately powered, lung cancer-specific evaluation. Similarly, prospective randomized data regarding regional anesthesia have failed to show a significant recurrence benefit in lung cancer surgery. For nonsteroidal anti-inflammatory drugs, the Adjuvant Low-dose ASpirin in Colorectal CAncer trial’s recent biomarker-driven success in colorectal cancer highlights the urgent necessity for analogous molecularly tailored investigations in non-small-cell lung cancer. Beyond pharmacological agents, meticulous physiological optimization remains critical: lung-protective ventilation, restrictive-to-euvolemic fluid management, and maintaining normothermia are biologically coherent strategies that preserve the endothelial glycocalyx, optimize interstitial fluid pressure, and maintain natural killer cell function. Summary Current clinical evidence does not justify selecting individual anesthetic agents solely for oncological benefit. Nevertheless, combining tailored pharmacological strategies, specifically opioid-sparing multimodal analgesia, with meticulous physiological optimization into a structured ‘oncoanesthesia care bundle’ provides a biologically coherent, low-risk framework available for immediate implementation. Future oncological trials must shift from pragmatic pan-cancer designs toward large-scale, patient-, cancer-, and gene-expression-specific trial protocols to truly capture personalized oncological outcomes.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: